REJUVIQ Trademark

Trademark Overview


On Tuesday, January 23, 2018, a trademark application was filed for REJUVIQ with the United States Patent and Trademark Office. The USPTO has given the REJUVIQ trademark a serial number of 87766080. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 10, 2021. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The REJUVIQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals preparations for the prevention and treatment of central nervous system disorders; Pharmaceuticals preparations for the prevention and treatment of circulatory systems disorders; Pharmaceuticals preparations for the prevention and treatment of sensory organs disorders; Pharmaceuticals preparations for the prevention and treatment of urogenital organs disorders; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Contraceptive preparations; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Fertility enhancing preparations; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention and treatmen...
rejuviq

General Information


Serial Number87766080
Word MarkREJUVIQ
Filing DateTuesday, January 23, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 10, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 14, 2018

Trademark Statements


Goods and ServicesPharmaceuticals preparations for the prevention and treatment of central nervous system disorders; Pharmaceuticals preparations for the prevention and treatment of circulatory systems disorders; Pharmaceuticals preparations for the prevention and treatment of sensory organs disorders; Pharmaceuticals preparations for the prevention and treatment of urogenital organs disorders; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Contraceptive preparations; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Fertility enhancing preparations; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, February 2, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Trademark Events


Event DateEvent Description
Monday, May 10, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 10, 2021ABANDONMENT - NO USE STATEMENT FILED
Saturday, October 3, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 1, 2020EXTENSION 4 GRANTED
Thursday, October 1, 2020EXTENSION 4 FILED
Thursday, October 1, 2020TEAS EXTENSION RECEIVED
Wednesday, April 8, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 6, 2020EXTENSION 3 GRANTED
Monday, April 6, 2020EXTENSION 3 FILED
Monday, April 6, 2020TEAS EXTENSION RECEIVED
Tuesday, October 8, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 4, 2019EXTENSION 2 GRANTED
Friday, October 4, 2019EXTENSION 2 FILED
Friday, October 4, 2019TEAS EXTENSION RECEIVED
Saturday, April 6, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 4, 2019EXTENSION 1 GRANTED
Thursday, April 4, 2019EXTENSION 1 FILED
Thursday, April 4, 2019TEAS EXTENSION RECEIVED
Tuesday, October 9, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 14, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 14, 2018PUBLISHED FOR OPPOSITION
Wednesday, July 25, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, July 9, 2018ASSIGNED TO LIE
Saturday, June 23, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, June 8, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 7, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 7, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, March 25, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, March 25, 2018NON-FINAL ACTION E-MAILED
Sunday, March 25, 2018NON-FINAL ACTION WRITTEN
Saturday, March 24, 2018ASSIGNED TO EXAMINER
Friday, February 2, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, January 26, 2018NEW APPLICATION ENTERED IN TRAM